ORICORIC Pharmaceuticals, Inc.
$13.17+9.0% 1Y
$13.17
$7.4752 weeks$14.67
Price
+9.0%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for ORIC today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$1.36B
1 year+9.0%
5 years-19%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 23, 2026The Program Update covered updated data from the Company’s Phase 1b trial of enozertinib, as well as the Company’s plans to initiate a global Phase 3 registrational trial of enozertinib in the first half of 2027: Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC Enozertinib is being evaluated in an ongoing Phase 1b …Regulation FD disclosure · Form 8-K
- Aug 3, 2026ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates.Earnings release · press release
- Jul 30, 2026Effective July 28, 2026, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), in order to increase the number of shares reserved for issuance under the …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.